SPM 928
Latest Information Update: 25 Nov 2016
At a glance
- Originator ARYx Therapeutics; Schwarz Pharma
- Class
- Mechanism of Action Potassium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 01 Aug 2003 Discontinued - Preclinical for Arrhythmias in USA (unspecified route)
- 11 Jan 2000 Preclinical development for Arrhythmias in USA (Unknown route)
- 10 Jan 2000 New profile